RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B. It is an orally-available prodrug of isatoribine, that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.